Despite improvements in disease-free and overall survival resulting from the use of adjuvant chemotherapy in patients with lymph node-positive breast cancer, a significant number of patients develop tumor recurrence and die from the disease. Therefore, there is a need to develop new treatment regimens that combine active drugs for the treatment of such patients and to test alternative schedules and agents.I am very actively involved with the NSABP and am the Protocol Chair for NSABP B30. The primary aims of this Phase III multinational trial are 1) to determine whether four cycles of post-operative doxorubicin (A), docetaxel (T), and cyclophosphamide (C) administered concurrently will more effectively prolong disease-free survival and overall survival of patients with lymph node-positive breast cancer than will 4 cycles of AC followed by 4 cycles of T, and 2) to determine whether 4 cycles of AT is at least as efficacious as the above two regimens. The rationale for the design of the study was the significant efficacy of docetaxel in patients withmetastatic breast cancer and the improved activity when used in combination with anthracyclines. The hypothesis is that concurrent combination with an active taxane is more important than the sequence or duration of therapy. The second hypothesis for the study is that cyclophosphamide is not essential for a survival benefit when used in combination with the two most active agents for breast cancer. The standard arm for this study is the AC followed by T arm because it was the experimental arm for the NSABP B27 study. The secondary aims of the study are to compare toxicities, to examine differences in amenorrhea in premenopausal women in each treatment arm and its relationship to symptoms, quality of life (QOL), disease-free survival and overall survival, and finally to compare the quality of life among patients in each of the three treatment arms.Ovarian damage is considered the most significant long-term sequela of adjuvant chemotherapy in premenopausal breast cancer survivors, and alkylating agents such as cyclophosphamide are often the cause of ovarian dysfunction. Furthermore, drug-induced amenorrhea may be a favorable prognostic factor in patients with breast cancer, although this is controversial. NSABP B-30 will compare the incidence of amenorrhea in each treatment arm of the study and will assess the association of amenorrhea with symptoms and quality of life. (Because the AT arm does not include cyclophosphamide, there may be less ovarian dysfunction with this regimen.) Documenting menstrual history in women participating in this protocol will provide a unique opportunity to assess the effect of induced menopause on disease-free and overall survival. A menstrual history study, which included a baseline and follow-up questionnaires at cycle 4, and at 6, 12, 18, and 24 months, was implemented in this trial. QOL assessments are an attempt to measure and scientifically analyze the impact of a disease and its treatment on patients' perception of their well-being. Studies have shown that, at the end of primary treatment for breast cancer, women report decreased physical functioning after chemotherapy. QOL will be assessed in NSABP B-30 by Functional Assessment of Cancer Therapy - Breast (FACT-B), Treatment-Specific Symptom Checklist, Vitality Scale (SF -36) and Quality of Life Rating Scale at the same time points as those for the menstrual history study. QOL assessment can be helpful in weighing the risk and benefits of treatment options, particularly when differences in disease-free and overall survival among the treatment options are small. The NSABP B-30 study began accrual in March 1999 and completed accrual of 5351 patients in March 2004. The expected reporting of the results is in 2007. There were 610 patients included in a preliminary report of the menstrual history study at the American Society of Clinical Oncology meeting.

Agency
National Institute of Health (NIH)
Institute
Division of Basic Sciences - NCI (NCI)
Type
Intramural Research (Z01)
Project #
1Z01BC010560-02
Application #
7291868
Study Section
(MOB)
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
2005
Total Cost
Indirect Cost
Name
Basic Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Korde, Larissa A; Lusa, Lara; McShane, Lisa et al. (2010) Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer. Breast Cancer Res Treat 119:685-99
Yang, Sherry X; Steinberg, Seth M; Nguyen, Dat et al. (2008) Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer. Clin Cancer Res 14:5893-9
Denduluri, Neelima; Lee, James J; Walshe, Janice et al. (2007) Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer. Invest New Drugs 25:63-7
Dennison, Sheri K; Jacobs, Samuel A; Wilson, John W et al. (2007) A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer. Invest New Drugs 25:545-51
Yang, Sherry X; Hewitt, Stephen M; Steinberg, Seth M et al. (2007) Expression levels of eIF4E, VEGF, and cyclin D1, and correlation of eIF4E with VEGF and cyclin D1 in multi-tumor tissue microarray. Oncol Rep 17:281-7
Denduluri, Neelima; Low, Jennifer A; Lee, James J et al. (2007) Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol 25:3421-7
Walshe, Janice M; Berman, Arlene W; Vatas, Ujala et al. (2007) A prospective study of adjuvant CMF in males with node positive breast cancer: 20-year follow-up. Breast Cancer Res Treat 103:177-83
Portera, Chia C; Swain, Sandra M (2007) The heart of the matter. J Clin Oncol 25:3794-6
Thukral, Arpi; Thomasson, David M; Chow, Catherine K et al. (2007) Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab--initial experience. Radiology 244:727-35
Orzano, Jennifer A; Swain, Sandra M (2005) Concepts and clinical trials of dose-dense chemotherapy for breast cancer . Clin Breast Cancer 6:402-11

Showing the most recent 10 out of 14 publications